Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Key facts

Sponsor

Paratek Pharmaceuticals Inc

Principal Investigator

Amy Manley

Paratek Pharmaceuticals Inc

Intervention

Omadacycline Oral Tablet(drug)

Enrollment

66 target

Eligibility

18 years · All sexes

Timeline

2021 – 2024

Study locations (17)

• Stanford University, Stanford, California, United States
• Georgetown University Hospital, Washington D.C., District of Columbia, United States
• St. Francis Medical Institute, Clearwater, Florida, United States
• University of Miami, Miami, Florida, United States
• University of South Florida, Tampa, Florida, United States
• Infectious Disease Consultants of the Treasure Coast, Vero Beach, Florida, United States
• Emory University School of Medicine, Atlanta, Georgia, United States
• Louisiana State University Medical Center Health Sciences Center-New Orleans Section of Pulmonary/Critical Care & Allergy/Immunology, New Orleans, Louisiana, United States
• Johns Hopkins University, Baltimore, Maryland, United States
• Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
• Northwell Health, New Hyde Park, New York, United States
• Einstein/Montefiore Medical Center, The Bronx, New York, United States
• University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
• Oregon Health & Science University, Portland, Oregon, United States
• Medical University of South Carolina (MUSC), Charleston, South Carolina, United States
• +2 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Pulmonary non-tuberculous mycobacterial infection

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE1NCT07228702
  Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection
  Vancouver Coastal Health
• RECRUITINGNANCT07192705
  Health Impact of Non-Tuberculous Mycobacteria Pulmonary Disease (NTM-PD)
  University College, London
• RECRUITINGPHASE4NCT07213765
  Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease
  Bin Cao
• RECRUITINGPHASE4NCT07084402
  Short-term Bactericidal Effect of Contezolid in MAC-PD
  Bin Cao
• RECRUITINGPHASE4NCT07174076
  Prevention of Recurrence With Cordyceps Sinensis in Mycobacterium Avium Complex Pulmonary Disease
  Bin Cao
• RECRUITINGNCT07131774
  Treatment Monitoring for NTM Infections With a Symptom Diary
  Research Center Borstel
• RECRUITINGNCT06815588
  Improving the Outcomes of Children With Tuberculosis Through Innovative Diagnostics and Treatment Monitoring
  Research Center Borstel
• RECRUITINGNCT05906316
  A Prospective, Multicenter, Single-arm MAC-PD Cohort: a NTM-NET and ESGMYC Collaborative Study
  Radboud University Medical Center

See all trials for Pulmonary non-tuberculous mycobacterial infection →